Skip to main content

COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Inverse Probability of Treatment Weighting Analysis

    Basic Details
    Date Posted
    In progress
    Medical Product
    proton pump inhibitors
    Health Outcome(s)
    COVID-19 hospitalization
    Severe COVID-19

    This analysis investigates risk of COVID-19-related hospitalization and severe COVID-19 (COVID-19-related hospitalization requiring intubation, mechanical ventilation or intensive care unit [ICU] admission; or inpatient death during a COVID-19 hospitalization) among a population of proton pump inhibitor (PPI) new users with gastroesophageal reflux disease (GERD) compared to a population of famotidine new users with GERD. 

    The study period includes data from April 1, 2020 to October 1, 2020. We distributed this request to five Sentinel Data Partners on June 1, 2023.

    The analytic package associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.